Diabetic Retinopathy (DR)

DR is a microvascular complication of diabetes leading to retinal ischemia, neovascularization, and vision loss. Early detection through annual eye exams and strict metabolic control dramatically reduces blindness.

Pathophysiology & Stages

• Nonproliferative DR (NPDR): microaneurysms, intraretinal hemorrhages, venous beading, IRMA
• Proliferative DR (PDR): neovascularization, vitreous hemorrhage, tractional retinal detachment
• Diabetic Macular Edema (DME): leakage causing central vision loss, can occur at any stage

Risk Factors

• Duration of diabetes, poor glycemic control (A1C)
• Hypertension, dyslipidemia, kidney disease
• Pregnancy, puberty
• Smoking, sleep apnea

Symptoms

• Often asymptomatic until advanced
• Blurred or fluctuating vision
• Dark spots, floaters, flashes
• Sudden vision loss (vitreous hemorrhage or detachment)

Screening

• Type 1 diabetes: first exam 5 years after diagnosis
• Type 2 diabetes: at diagnosis
• Pregnant patients with diabetes: before conception or during first trimester
• Annual dilated exams; more frequent if DR present
• Teleophthalmology programs improve access

Diagnosis & Monitoring

• Dilated fundus examination
• Fundus photography for documentation
• Optical coherence tomography (OCT) for macular edema
• Fluorescein angiography for treatment planning

Treatment & Management

Systemic Control

• Tight glycemic control (A1C <7%), BP <130/80, lipid optimization
• Weight management, exercise, smoking cessation

Ocular Therapies

• Anti-VEGF injections (ranibizumab, aflibercept, bevacizumab, faricimab) for DME/PDR
• Intravitreal steroids (dexamethasone implant) for refractory DME (monitor IOP/cataract)
• Panretinal photocoagulation (PRP) for proliferative disease
• Focal/grid laser for focal DME (less common now)
• Pars plana vitrectomy for non-clearing vitreous hemorrhage or tractional detachment

Living with DR

• Track A1C, BP, lipids, eye exam results, injection schedules
• Maintain consistent diabetes care team follow-up
• Use low-vision aids if needed
• Manage mental health; vision anxiety is common

Complications

• Macular edema, vitreous hemorrhage
• Tractional retinal detachment
• Neovascular glaucoma
• Blindness if untreated

Research & Future Directions

Focus areas include sustained-release anti-VEGF delivery, gene therapy, early biomarkers, and combined systemic + ocular therapies.

Experimental & Emerging Treatments

• Port Delivery Systems: Refillable implants releasing anti-VEGF for months at a time.
• Gene Therapy: AAV vectors aiming for long-term VEGF inhibition.
• Modulators of Neuroinflammation: Target microglial activation to protect retinal neurons.
• Digital Retinal Analytics: AI screening tools for primary care clinics and wearables tracking glycemic variability’s impact on microvasculature.

Track DR with Diagnoza.care

Make Every Eye Exam Count – Log A1C/BP/lipid trends, ophthalmology reports, OCT results, injection dates, systemic meds, and lifestyle habits; capture side effects; and let the AI companion remind you of upcoming exams and highlight correlations between metabolic control and vision.

---

Medical Disclaimer: Informational only. Follow your ophthalmologist/endocrinologist for screening intervals, treatment decisions, and metabolic optimization. Sources: American Diabetes Association, American Academy of Ophthalmology, National Eye Institute